ISCORT 14

Transcription

ISCORT 14

Scientific Program
ISCORT 14
27.01.15 - 31.01.15, Eilat, Israel
The Annual Meeting of the Israeli Society for
Clinical Oncology and Radiation Therapy
ISCORT wishes to express its gratitude to the following companies
for their support of the 14th ISCORT Annual Meeting:
Organizing Committe
Platinum Sponsor
Roche Pharmaceuticals (Israel) Ltd
President: Prof. Ron Epelbaum
Secretary: Dr. Ravit Geva
Gold Sponsor
Astrazeneca
Medison
MSD
Novartis
Pfizer
Teva
Silver Sponsor
Bayer
BMS
Boehringer-Ingelheim
Eli Lilly
Janssen
Merck Serono
Nanostring technologies
Bronze Sponsor
Astellas
CancerHope
Champions Oncology
Ferring
GSK
ISI
Mediline
Neopharm
RAFA
Sanofi
Scientific Committe
ISCORT 14
Organizing Company
I.M. Knasim Ltd.
‫ פרופ' רון אפלבוים‬:‫נשיא הכנס‬
‫ ד"ר רוית גבע‬:‫מזכירת הכנס‬
ISCORT 14
Prof. David Geffen, Chairman
Prof. Shmuel Ariad
Dr. Gil Bar-Sela
Prof. Baruch Brenner
Prof. Jacob Gopas
Prof. Nissim Haim
Dr. Rinat Yerushalmi
Dr. Yaacov Lawrence
Prof. Michal Lotem
Dr. Rafi Pfeffer
Prof. Benjamin Corn
Dr. Eli Rosenbaum
Prof. Salomon Stemmer
‫הוועדה המארגנת‬
‫הוועדה המדעית‬
‫ יו"ר‬,‫פרופ' דוד גפן‬
‫פרופ' שמואל אריעד‬
‫דר' גיל בר סלע‬
‫פרופ' ברוך ברנר‬
)‫פרופ' יעקב גופס (מדעי יסוד‬
‫פרופ' נסים חיים‬
‫דר' רינת ירושלמי‬
‫דר' יעקב לורנס‬
‫פרופ' מיכל לוטם‬
‫דר' רפאל פפר‬
‫פרופ' בנימין קורן‬
‫דר' אלי רוזנבאום‬
‫פרופ' סלומון שטמר‬
‫החברה המארגנת‬
‫ כנסים בע"מ‬.‫מ‬.‫א‬
Dear Friends,
Welcome to ISCORT 14, the 14th Annual Conference of the Israeli
Society for Clinical Oncology and Radiation Therapy, being held in
Eilat on January 27-31, 2015. In recent years, developments and
innovations in cancer research and treatment have been quick and
major. The present conference gives us the opportunity to be updated
on the great progress that occurred in clinical oncology, radiotherapy,
and cancer basic research.
This conference, with the participation of leading experts from Israel
and abroad, includes three main sessions on lung cancer, gastrointestinal cancer and breast cancer, a fourth session will cover other
tumors. Additional sessions will focus on innovations in genomics,
immunotherapy and radiotherapy. The familiar lecture format will be
joined by clinical discussions in the form of tumor boards and debates.
It will be interesting!
We would specifically like to draw your attention to the three keynote
lectures given on the first and last days of the conference, and to the
open discussions on Friday discussing two important and “hot” topics
related to oncological activity in Israel.
We consider ISCORT as an important platform for presenting the
original clinical and basic science studies of its members. A unique
session will present the three research proposals competing for the
ISCORT Research Grant. The choice of the winner is largely in your
hands, so your presence is important, as each vote can influence
the result.
The Scientific Committee, headed by Prof. David Geffen, chose the
best scientific work in the field of oncology in Israel. We would like
to express our deep appreciation and gratitude for their excellent
and devoted work.
We hope you will enjoy the rich and varied professional program,
and also the social and cultural atmosphere around. And, yes, have
some rest too.
,‫חברים יקרים‬
‫עשר של האיגוד הישראלי‬-‫ הכינוס השנתי הארבעה‬,ISCORT 14 ‫ברוכים הבאים לכנס‬
.2015 ‫ בינואר‬27-31 ‫ שמתקיים באילת בין התאריכים‬,‫לאונקולוגיה קלינית ורדיותרפיה‬
‫ההתפתחויות והחידושים בחקר הסרטן ובטיפול בו בשנים האחרונות מהירים ביותר‬
‫ הכנס הנוכחי נותן לנו הזדמנות להתעדכן אודות ההתקדמות‬.‫וגדולים בהיקפם‬
‫ כמו גם‬,‫הרבה שחלה בתחומים השונים של האונקולוגיה הקלינית והרדיותרפיה‬
.‫במחקר הבסיסי הרלבנטי‬
‫ בנוי בצורת‬,‫ ובו משתתפים מומחים מובילים בתחומם מהארץ ומהעולם‬,‫הכנס‬
‫ מערכת‬,‫ שלשה מושבים עיקריים ידונו בהתפתחויות בנושאי סרטן הריאה‬.‫מושבים‬
‫ בנוסף יתקיימו מושבים‬.‫ ומושב רביעי עוסק בגידולים שונים אחרים‬,‫העיכול והשד‬
"‫ בכנס זה אנו "מתבלים‬.‫ אימונותרפיה ורדיותרפיה‬,‫שיתמקדו בחידושים בגנומיקה‬
tumor boards ‫את פורמט ההרצאות המוכר והטוב בדיונים קליניים בצורת‬
!‫ יהיה מעניין‬.debates-‫ו‬
‫ שתינתנה בימים‬keynote lectures-‫אנו רוצים לציין באופן מיוחד את שלושת ה‬
‫ וכן את הדיונים ביום שישי שבהם תוכלו להתווכח ולהביע‬,‫הראשון והאחרון של הכנס‬
.‫"חמות" הקשורות בפעילות האונקולוגית בארץ‬-‫ סוגיות חשובות ו‬2-‫דעה ב‬
‫אנו רואים בכנס האונקולוגי השנתי במה חשובה להצגת העבודות המקוריות הקליניות‬
‫ אלו שולבו במושבים השונים ע"פ הנושאים הנידונים‬.‫והמחקריות של חברי האיגוד‬
‫ הצעות המחקר שנבחרו להשתתף‬3-‫ בנוסף יש מושב מיוחד בו נתוודע ל‬.‫בהם‬
‫ הבחירה בהצעה המנצחת היא בעיקרה‬.‫בתחרות על מענק המחקר של האיגוד‬
.‫בידיכם ועל כן נוכחותכם חשובה וכל קול קובע‬
‫הוועדה המדעית ברשותו של פרופ' דוד גפן שבחרה את מיטב היצירה המדעית‬
‫ ועל כך יבואו‬,‫בארץ בתחום האונקולוגיה עשתה עבודתה במסירות ובמקצועיות רבה‬
.‫חברי הוועדה על הברכה והתודה‬
‫ ובנוסף תזכו‬,‫אנו מקווים שתיהנו מהתכנית המקצועית העשירה והמגוונת של הכנס‬
...‫ גם לקצת מנוחה‬,‫ וכן‬,‫להנאה חברתית ותרבותית בשהייתכם כאן‬
Sincerely,
Prof. Ron Epelbaum
ISCORT 14, President
,‫בברכה‬
Dr. Ravit Geva
ISCORT 14, Secretary
‫ד"ר רוית גבע‬
ISCORT 14 ,‫מזכירת הכנס‬
‫פרופ' רון אפלבוים‬
ISCORT 14 ,‫נשיא הכנס‬
Tuesday, January 27, 2015
17:00-17:20
17:20-18:05
17:25-17:35
17:35-17:45
17:45-17:55
Opening ceremony
Greetings and best residents award
Moderator: Dr. Ravit Geva,
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Speakers: Dr. Wilmosh Mermershtain,
ISCORT President, Soroka Medical Center,
Beer-Sheva, Israel
Mrs. Miri Ziv,
CEO, Israel Cancer Association, Givataym, Israel
Prof. Ron Epelbaum,
Conference President,
Rambam Health Care Campus, Haifa, Israel
The best of ISCORT
Moderators: Prof. David Geffen,
Soroka Medical Center, Beer-Sheva, Israel
Prof. Nissim Haim,
Abstract # 1304
A phase I study of mitomycin-C prodrug
in pegylated liposomes
Prof. Alberto Gabizon,
Shaare Zedek, Jerusalem, Israel
Abstract # 903
Association between variants of
5-hydroxytryptamine receptor 3C (HTR3C) and
chemotherapy-induced symptoms in women
receiving adjuvant treatment for breast cancer
Dr. Ido Wolf,
Abstract # 316
Early detection of lung cancer (LCD) by fishbased sputum test
Prof. Nir Peled,
Rabin Medical Center, Petach-Tikva, Israel
17:55-18:05
Discussion
Prof. David Geffen,
18:05-19:15 Keynote lectures
Moderators: Dr. Ravit Geva,
Prof. Ron Epelbaum,
18:05-18:30
Cancer Prevention Prof. Nadir Arber,
Supported by ISCORT
18:30-19:15
The wisdom of the crowd: From Bacteria to the
cyberwar between cancer and the
immune system
Prof. Eshel Ben-Jacob,
Tel Aviv University, Tel-Aviv, Israel Supported by Merck Serono
19:30-21:00
Dinner
Wednesday, January 28, 2015
08:00-10:00 Lung Cancer - Part I
08:00-09:05
Moderators: Dr. Jair Bar,
Sheba Medical Center, Ramat-Gan, Israel
Prof. Shmuel Ariad,
08:00-08:20
Lung cancer in Israel: Data from the Israel
National Cancer Registry
Dr. Barbara Silverman,
Israel National Cancer Registry, Israel
Supported by Roche
08:20-08:30
08:30-09:05
Advanced squamous cell lung cancer the past,
present and near future
Dr. Abed Agbarya,
Assuta Medical Center, Haifa, Israel
Invited session, Supported by Lilly
Educational
New horizons in advanced squamous cell lung
cancer treatment: Squire and Revel trials
Prof. Nick Thatcher,
University of Manchester, UK
Supported by Lilly
09:10-10:00 Moderator: Prof. Hovav Nechushtan,
Hadassah Hebrew University Medical Center,
Jerusalem, Israel
09:10-09:35
The evolving treatment paradigm in
adenocarcinoma of the lung
Dr. Natalie Maimon-Rabinovich,
Meir Medical Center, Kfar-Saba, Israel
Supported by Roche
09:35-10:00
Targeting angiogenesis in NSCLC Dr. Maya Gottfried,
Supported by BI
10:00-10:30
Coffee Break
10:30-13:00
Lung Cancer - Part II
10:30-11:20
Moderator: Prof. Ofer Merimsky,
10:30-10:55
EML4 - ALK positive lung cancer,
1st line therapy and beyond
Prof. Nir Peled,
Supported by Pfizer
10:55 -11:20 Evolving treatment paradigms for NSCLC
treatment resistances
Dr. Dov Hershkovitz,
Supported by Astrazeneca
11:20-12:20
12:20-13:00
12:20-12:30
Tumor board - Lung cancer
Moderator: Dr. Maya Gottfried,
Panel: Dr. Alon Aharon,
Prof. Rivka Zissin,
Dr. Alon Ben Nun,
Sheba Medical Center, Israel
Prof. Ofer Merimsky,
Top lung cancer abstracts
Moderators: Dr. Shoshana Keren,
Lin Medical Center, Haifa, Israel
Dr. Julia Dudnik,
Abstract # 318
Oral glucose tolerance test as a breath challenge
diagnostic test in lung cancer Dr. Layah Alkoby,
Wednesday, January 28, 2015 (Continued)
12:30-12:40
12:40-12:50
Abstract # 309
A prospective, open-label, multi-center,
single-arm study investigating the correlation
between erlotinib induced rash and efficacy
in epidermal growth factor receptor (EGFR) Mutated advanced non-small cell lung cancer
(NSCLC) patients receiving first-line therapy
Dr. Maya Gottfried,
Abstract # 312
Heparanase procoagulant activity is elevated and
predicts survival in non-small cell lung cancer
patients
Prof. Nissim Haim,
13:00-14:00
Lunch
14:00-16:00
Immunotherapy
14:00-14:45
Educational
Immunotherapy - A new era in cancer treatment
Prof. Tanguy Seiwert,
University of Chicago, USA
Supported by MSD
14:45-15:10
Immunotherapy - The modern approach to the
treatment of melanoma
Prof. Jacob Schachter,
Supported by BMS
Moderators: Prof. Jacob Schachter,
Dr. Orit Gotfeld,
15:10-15:35
Anti-PD1 in H&N cancer
Prof. Tanguy Seiwert,
University of Chicago, USA
Supported by MSD
15:35-16:00
Advances in Immunotherapy for the
treatment of lung cancer
Dr. Jair Bar,
Supported by Roche
16:00-16:30
Coffee Break
16:30-18:15
Additional tumors (But not less important…)
16:30-17:45
Moderators: Dr. Safra Tamar,
Dr. Eli Rosenbaum,
16:30-16:55
Identifying the appropriate treatment for
locally advance BCC patients:
A multidisciplinary team approach
Prof. Eyal Fenig,
Prof. Yosef Elkalay,
Assuta Medical Center, Tel-Aviv, Israel
Supported by Roche
16:55-17:20
Treatment approaches for cervical cancer
Prof. Tally Levy,
Wolfson Medical Center, Holon, Israel
Supported by Roche
17:20-17:45
Precision medicine for prostate cancer:
Transitioning from drug to therapy
development
Prof. Eleni Efstathiou,
M.D. Anderson Cancer Center,
Houston, USA
Supported by Janssen
Wednesday, January 28, 2015 (Continued)
Thursday, January 29, 2015
17:45-18:15
Top additional tumors abstracts - Part I
Moderators: Prof. Avishay Sella,
Assaf Harofeh Medical Center, Zerifin, Israel
Dr. Ronnie Shapira,
08:00-10:30
Breast Cancer
08:00-08:50
Moderator: Dr. Rinat Yerushalmi,
17:45-17:55
Abstract # 1301
The aging suppressor hormone klotho: A novel
tumor suppressor and regulator of IGF-1 and
estrogen signaling in ovarian cancer Dr. Ido Wolf,
08:00-08:25
CDK 4/6 Inhibition - New mechanism, new hope
Prof. Bella Kaufman,
Supported by Pfizer
08:25-08:50
New and evolving treatments for HER2+ breast
cancer: Raising The Bar
Prof. Hope Rugo,
University of California, San Francisco, USA
Supported by Roche
17:55-18:05
18:05-18:15
Abstract # 403
Patients with the rare subtype of metastatic
papillary renal cell carcinoma (RCC) who may
benefit from sunitinib therapy (TX): Results from
a Large International Metastatic RCC Database
Dr. Daniel Keizman,
Abstract # 409
A single-arm, multicenter, open-label phase II
trial of cabazitaxel as second-line treatment
for patients with locally advanced or metastatic
transitional cell carcinoma (TCC)
Dr. Avivit Peer,
19:00-21:00
Dinner
21:00 Social Event
08:50-09:50
09:50-10:30
Tumor board - Breast cancer
Moderator: Dr. Noa Ben-Baruch,
Kaplan Medical Center, Rehovot, Israel
Panel: Prof. Moshe Inbar,
Dr. Merav Ben-David,
Sheba Medcial Center, Ramat-Gan, Israel
Dr. Yuliana Weinstein,
Dr. Tanir Allweis,
Top Breast cancer abstracts
Moderators: Dr. Larisa Ryvo,
Dr. Karen Drumea,
Wednesday,
Thursday,
January
January
29,28,
2015
2015
(Continued)
(Continued)
09:50-10:00
10:00-10:10
10:10-10:20
Abstract # 7
Ten-year analyses of the big 2-98 phase III
Trial with pooled analysis on the role of KI67
in predicting benefit of adjuvant docetaxel in
patients with oestrogen receptor positive
breast cancer Dr. Amir Sonnenblick,
Institute Jules Bordet, Bruxelles, Belgium
Abstract # 901
The role of breast cancer cell microparticles in
thrombogenicity, angiogenesis and apoptosis
following chemotherapy
Dr. Gil Bar-Sela,
Abstract # 9
Earlier age of breast cancer onset in Israeli
BRCA carriers-anticipation or selection
bias effect
Dr. Rinat Yerushalmi,
10:30-11:00
Coffee break
11:00-13:30
Genomics (Parallel Session I - Main Hall)
11:00-13:00
Moderators: Prof. Bella Kaufman,
Prof. Ilan Ron,
11:00-11:45
Educational
Clinical implications of intrinsic molecular
subtypes of cancer
Dr. Aleix Prat,
Hospital Clinic De Barcelona, Barcelona, Spain
Supported by Nanostring
11:45-12:10
12:10-12:35
12:35-13:00
13:00-13:30
13:00-13:15
13:15-13:30
11:00-13:30
11:00-11:05
11:05-11:30
Genetic alterations and management
of ALK+ in NSCLC
Dr. Enriqueta Felip,
Vall d’Hebron University Hospital, Barcelona, Spain
Supported by Novartis
Molecular diagnostics and treatment practices
from EGFR and KRAS to NGS panels and germline
mutations in BRCA
Prof. Gad Rennert,
Carmel Medical Center, Haifa, Israel
Supported by Astrazeneca
The role of molecular profiling for patients with
ductal carcinoma in situ (DCIS) of the breast
Prof. Lawrence J. Solin, MD, FACR, FASTRO,
University of Pensylvania, Philadelphia, PA. USA
Supported by Teva
Moderator: Dr. Asher Shalmon
Jerusalem, Israel
Genetics subtypes in colon cancer - Are we really there?
Prof. Dan Aderka,
Is proteomics the new genomics?
Dr. Ido Wolf,
Radiotherapy (Parallel Session II - Tarshish
Hall, 1st floor)
Greetings
Dr. Rafi Pfeffer,
Moderator: Dr. Zvi Symon,
Sheba Medial Center, Ramat-Gan, Israel
Reviewing the TARGIT Trial of intra-operative
radiotherapy for early breast cancer - latest results,
patient selection and indications for treatment
Prof. Jeffrey S Tobias,
University College London, London, UK
Supported by Medison
Wednesday,
Thursday,
January
January
29,28,
2015
2015
(Continued)
(Continued)
12:50-13:00
11:30-12:00
Moderator: Dr. Rafi Pfeffer,
Radiation dose escalation in locally advanced
NSCLC: Back to the past?
Dr. Benjamin Movsas,
Henry Ford Hospital, Detroit, Michigan, USA
Moderator: Dr. Amichay Meirovitz,
Jerusalem, Israel
Advances in radiotherapy for unresectable
pancreatic cancer
Prof. Edgar Ben-Josef,
University of Pennsylvania, Philadelphia, USA
12:00-12:20
12:20-12:40
12:40-13:30
12:40-12:50
Moderator: Dr. Gideon Marshak,
Clalit Health Services, Tel-Aviv, Israel
Head and neck radiation technology: Where are
we going?
Dr. Salem Billan,
Top radiotherapy abstracts
Moderators: Prof. Rami Ben-Yosef,
Prof. Eyal Fenig,
Abstract # 1005
The first reported use of continuous positive
airway pressure (CPAP) in patients receiving
stereotactic body radiation therapy (SBRT): A
prospective trial studying the effect on tumor
motion and dose to critical organs
Dr. Sarit Appel,
13:00-13:10
13:10-13:20
Abstract # 1009
Image guided radiation therapy (IGRT) reduces
gastrointestinal (GI) and genitourinary (GU)
toxicity when radiating the prostate fossa (PF)
Dr. Benjamin Spieler,
Abstract # 1010
Actively targeted gold nanoparticles as novel
radiosensitizer agents: In vivo head and neck
cancer model
Dr. Aharon Popovtzer,
Abstract # 313
Stereotactic radiotherapy (SBRT) in the
treatment of centrally located tumors, a single
institution experience
Dr. Yasmin Korzets-Ceder,
13:30-14:30
Lunch
Conference will convene at
Tarshish Hall, 1st floor
14:30-16:30 GI Malignancies - Part I
14:30-14:55
Moderator: Dr. Efraim Idelevich,
Treatment of CRC in 2015: Daily practice
dilemmas and potential pitfalls
Prof. Baruch Brenner,
Supported by Roche
Wednesday,
Thursday,
January
January
29,28,
2015
2015
(Continued)
(Continued)
16:10-16:20
14:55-15:30
Debate – It’s time for chemotherapy alone in the
neoadjuvant treatment of rectal cancer
Moderators: Prof. Aharon Sulkes,
Prof. Adi Shani,
14:55-15:05
Pro: Dr. Alex Benny,
15:05-15:15
Con: Dr. Marc Wygoda,
Jerusalem, Israel
15:15-15:30
Open Discussion
15:30-16:00
Moderator: Dr. Sofia Man,
15:30-15:45
Major dilemmas in the management of
pancreatic cancer
Dr. Ravit Geva,
15:45-16:00
Major dilemmas in the management of
gastric cancer
Dr. Yakterina Shulman,
Hillel Yaffe Medical Center, Hadera, Israel
16:00-16:30
Top GI malignancies abstracts
Moderators: Dr. Thomas Tishler,
Shaare Zedek, Jerusalem, Israel
Dr. Alexander Gluzman,
16:00-16:10
Abstract # 211
CD24 and APC genetic polymorphisms in
pancreatic cancers – Do they have a role as
biomarkers for clinical outcome?
Dr. Sivan Shamai,
16:20-16:30
Abstract # 209
Colorectal cancer in young patients: A distinct
clinical entity or not?
Dr. Hadar Goldvaser,
Abstract # 212
Genetic features of lynch syndrome in the israeli
population
Dr. Yael Goldberg,
Jerusalem, Israel
16:30-17:00
Coffee break 17:00-18:00
GI Malignancies - Part II
17:00-18:00
Tumor board - Focus on GI malignancies liver spread
Moderator: Dr. Ayala Hubert,
Jerusalem, Israel
Panel: Prof. Arie Blachar,
Dr. Ido Nachmani,
Dr. Yaacov Lawrence,
Prof. Baruch Brenner,
18:00-18:25
Moderator: Prof. Baruch Klein,
The integration of SIRT into the treatment of
inoperable liver tumors
Dr. Gianluca Masi,
University of Pisa, Italy
Supported by Medison
19:00-21:00
Dinner
21:00
Social Event
Friday, January 30, 2015
08:00-08:30
Best grant proposal competition
08:00-08:30
Moderator: Dr. Raanan Berger,
Panel: Prof. David Geffen,
Prof. Hovav Nechushtan,
Jerusalem, Israel
Dr. Asher Shalmon,
Jerusalem, Israel
08:05-08:10
Update from last year’s winner
Dr. Valeria Semenisty,
08:10-08:15
Minimally invasive screening approach for early
detection of ovarian cancer
Dr. Keren Levanon,
08:15-08:20
08:20-08:25
Attitudes of oncologic patients towards
partecipation in clinical trials
Dr. Nethanel Asher
The contribution of host response to
chemotherapy-induced lymphangiogenesis and
its role in the clinical setting
Dr. Orit Kaidar–Person,
08:25-08:30
Vote and award best grant proposal award
08:30-08:35
Best published paper award 2014
Moderator: Prof. David Geffen,
08:35-09:05
09:05-10:05
09:05-09:45
09:05-09:20
09:20-09:45
09:45-10:05
09:45-09:55
09:55-10:05
10:05-10:30
10:30-11:00
Keynote lecture
Moderator: Dr. Rafi Pfeffer,
Assuta Medical Center,Tel-Aviv, Israel
The emerging role of SBRT for oligometastases
Prof. Benjamin Movsas,
Henry Ford Hospital, Detroit, Michigan, USA
Supportive Care
Moderator: Dr. Yaacov Baram,
The Baruch Padeh Medical Center, Poriya,
Tiberias, Israel
Palliative care expertise: should the oncologist care?
Dr. Gil Bar-Sela,
Rapid-onset opiates: Sophisticated drug delivery
to control breakthrough pain
Dr. Daniel Kurnik,
Supported by Teva
Top Supportive care abstracts
Moderator: Dr. Menachem Ben-Shahar,
Nahariya medical center, Nahariya, Israel
Abstract # 1104
Spiritual support amongst Israeli oncology patients
Dr. Yasmin Natan-Oz,
Abstract # 1101
The association between working alliance and
type of concerns, shared by advanced cancer
patients during chemotherapy
Dr. Gil Bar-Sela,
Coffee break
Top additional tumors abstracts - Part II
Moderators: Prof. Michal Lotem,
Jerusalem, Israel
Dr. Noam Asna,
Barzilai Medical Center, Ashkelon, Israel
Wednesday,
Friday,
January
January
30, 2015
28, 2015
(Continued)
(Continued)
10:30-10:40
10:40-10:50
10:50-11:00
11:00-11:15
11:15-12:35
11:15-11:55
11:15-11:25
11:25-11:35
Abstract # 909
Next generation sequencing (NGS) in soft tissue
sarcoma (STS) patients in israel
Dr. Sivan Shamai,
Abstract # 1303
Advances in the management of hepatocellular
carcinoma patients lead to improved survival
Dr. Assaf Moore,
Abstract # 801
Loss of ADAR1 is pivotal in the development of
metastatic melanoma
Dr. Gal Markel,
Geriatric oncology
Moderator: Prof. Yoram Cohen,
Ben-Gurion University of the Negev,
Beer-Sheva, Israel
Discussion on the recommendations of the
geriatric oncology national committee
Prof.Salomon Stemmer,
Debates in current oncology
Debate I
Should we perticipate in public advertising of
cancer drugs, will we be held accountable?
Moderator: Prof. Abraham Kuten,
Italian Hospital, Haifa, Israel
Pro: Dr. Raanan Berger,
Sheba Medical Center, Ramat-Gan, Israel Con: Dr. Wilmosh Mermershtain,
11:35-11:55
Open discussion
11:55-12:35
Debate II
Should radiotherapy and medical oncology finally
part as friends?
Moderator: Prof. Raphael Catane
11:55-12:05
Pro: Dr. Zvi Symon,
Sheba Medical Center, Ramat-Gan, Israel 12:05-12:15
Con: Prof. Beatrice Uziely,
Hadassah Hebrew University
Medical Center, Jerusalem, Israel
12:15-12:35
12:35-12:50
Open discussion
Regional collaborations
Moderator: Prof. Eli Gez,
The importance of regional collaborations in
oncology
Prof. Dr. Serdar Turhal,
Anadolu Medical Center, Istanbul, Turkey
12:50-13:00
Closing remarks
13:00-14:00
Lunch
14:00-15:00
ISCORT Assembly
19:00-21:00
Dinner
21:00
Social event
Prof. Ron Epelbaum,
Conference President,
Saturday, January 31, 2015
07:30-10:00
Breakfast
13:00-14:30
Lunch
16:00
Checkout
This programm was printed with the support of
Roche Pharmaceuticals (Israel) Ltd.

ISCORT 14

Transcription

Similar documents

final cover for program - The World Union of Jewish Studies

××¨××× ××ª×××××ª

סיכום החלטות מישיבת הנהלה מתאריך 27/4/2015

לוח בחינות סמסטר א

חברים יקרים, ברוכים הבאים לכנס iscort 14, הכינוס השנתי הארבעה

הכנס הישראלי הראשון לחקר רוחניות עכשווית

2011 - ISERD

תוכן עניינים

תל אביב הזמנה

מרתון 2014 - סכוליון - The Hebrew University of Jerusalem

אפידמיולוגיה תאורית שיטות וכלים

טבלת מחקרים מגייסים

בהארלם בית ספר לעברית - Ulpan-Or

2015 Annual Meeting

רשימת מחקרים קליניים מכון אונקולוגי 514233 מרכז רפואי אסף הרופא

שאלות ותשובות - עיריית תל-אביב-יפו

Clinical Neurology and Neurophysiology 2013

חוברת פעילות 2015-2014 - עיריית תל-אביב-יפו

VBF-iTEAM Program

הטיפול בסרטן השד

19 - ××× ×¡ × ×©× ×××××× ×××©×¨××× ××¤×¡××××××¨×× ××××××××ª

הכנס הבינלאומי השישי י של האגודה לחקר החינו היהוד